Study shows tofacitinib medication can fix porousness absconds in the digestive tract Kumar Jeetendra | October 6, 2020 A team of researchers led by biomedical scientist Declan F. McCole in the University of California, Riverside, has found that the medication tofacitinib, also called Xeljanz and approved by the FDA to treat rheumatoid arthritis and ulcerative colitis, can fix permeability defects in the intestine. Study results appear in the Journal of Crohn’s and Colitis. …
Polygenic threat ratings from multi-populace information should enhance IBD predictions Kumar Jeetendra | December 25, 2020 Using genetic data from nearly 30,000 individuals, Mount Sinai researchers have assembled hazard scores from a combination of datasets representing distinct ancestral populations that improve prediction of risk for inflammatory bowel diseases (IBD) including Crohn’s disease and ulcerative colitis. The research was published in Gastroenterology on December 24. The researchers found that polygenic risk scores, …
